Drug Trial Radar · NCT05753189
Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Feb 21, 2023
Primary completion
Feb 9, 2024
Study completion Feb 9, 2024
Sponsor
- Lead sponsor
- LENZ Therapeutics, IncAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subjects
Conditions
- Presbyopia
- Near Vision
- Refractive Error
- Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solutionDrug
Aceclidine + Brimonidine combination ophthalmic solution
Aceclidine ophthalmic solutionDrug
Aceclidine ophthalmic solution
VehicleDrug
Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Treatment-Related TEAETime frame: 7 visits over a total duration of approximately 28 weeks
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Site #326
Dothan, Alabama
Site #302
Chandler, Arizona
Site #320
Mesa, Arizona
Site #321
Phoenix, Arizona
Site #328
Phoenix, Arizona
Site #338
Scottsdale, Arizona
Site #331
Sun City, Arizona
Site #303
Garden Grove, California
Site #313
Glendale, California
Site #334
La Jolla, California
Site #322
Newport Beach, California
Site #306
Petaluma, California
Site #337
Rancho Cordova, California
Site #304
Santa Barbara, California
Site #308
Littleton, Colorado
Site #316
Danbury, Connecticut
Site #319
Crystal River, Florida
Site #309
Mt. Dora, Florida
Site #339
Morrow, Georgia
Site #340
Northbrook, Illinois
Site #317
Rock Island, Illinois
Site #301
Overland Park, Kansas
Site #307
Pittsburg, Kansas
Site #324
Louisville, Kentucky
Site #336
Alexandria, Minnesota
Site #330
Kansas City, Missouri
Site #325
St Louis, Missouri
Site #335
Bozeman, Montana
Site #341
Dover, New Jersey
Site #310
Fargo, North Dakota
Site #332
West Fargo, North Dakota
Site #329
Cincinnati, Ohio
Site #323
Powell, Ohio
Site #333
Eugene, Oregon
Site #312
Cranberry Township, Pennsylvania
Site #315
Memphis, Tennessee
Site #311
Smyrna, Tennessee
Site #314
El Paso, Texas
Site #318
San Antonio, Texas
Site #327
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.